Current Status of Co-Occurring Mood and Substance Use Disorders: A New Therapeutic Target

Abstract

Mood and substance use disorders commonly co-occur, yet there is little evidence-based research to guide the pharmacologic management of these comorbid disorders. The authors review the existing empirical findings, some of which may call into question current clinical pharmacotherapy practices for treating co-occurring mood and substance use disorders. The authors also highlight knowledge gaps that can serve as a basis for future research. The specific mood disorders reviewed are bipolar and major depressive disorders (either one co-occurring with a substance use disorder). Overall, findings from the relatively small amount of available data indicate that pharmacotherapy for managing mood symptoms can be effective in patients with substance dependence, although results have not been consistent across all studies. Also, in most studies, medications for managing mood symptoms did not appear to have an impact on the substance use disorder. In a recent trial for comorbid major depression and alcohol dependence, combination treatment with a medication for depression and another for alcohol dependence was found to reduce depressive symptoms and excessive drinking simultaneously. However, research has only begun to address optimal pharmacologic management of co-occurring disorders. In addition, current clinical treatment for alcohol and drug dependence often excludes new pharmacotherapies approved by the U.S. Food and Drug Administration for treating certain types of addiction. With new data becoming available, it appears that we need to revisit current practice in the pharmacological management of co-occurring mood and substance use disorders.

Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer

“…Given how patient characteristics and risk factors differ between HPV‐related and non–HPV‐related disease, it is perhaps not surprising that the associations were observed primarily in patients who were HPV‐negative. Behavioral risk factors (such as smoking and heavy alcohol consumption) tend to be more prevalent in HPV‐negative HNSCC, and these behaviors are often strongly correlated with psychosocial functioning and mood disorders . Such behaviors may also contribute to VEGF overexpression, although we did not observe such associations between behavioral risk factors and VEGF expression in the present study.…”

Gender‐specific effects of comorbid depression and anxiety on the propensity to drink in negative emotional states

“…Secondly, a potential benefit of early initiation of antidepressant treatment in alcoholics with comorbid depression has been demonstrated . Evidence also suggests improvement of alcohol and depression‐related outcomes with the combined use of antidepressants and anti‐dipsotropics and effectiveness of pharmacotherapy for mood symptoms in patients with substance dependence . However, not everyone treated responds to antidepressants or anti‐dipsotropics, and predictors of treatment response are needed.…”

Prospective Study of Substance-Induced and Independent Major Depressive Disorder Among Individuals With Substance Use Disorders in a Nationally Representative Sample

“…Withholding treatment for depression among individuals diagnosed with SIDD may also contribute to more severe SUD outcomes in this group . For both SIDD and MDD‐SUD, findings suggest the potential utility of integrated behavioral and pharmacological treatments for depression and substance use comorbidity to account for the bidirectional impact symptoms may have on the course of each disorder . Further, if the SIDD diagnosis actually reflects the development of MDD precipitated by an SUD, effectively treating symptoms of an SUD may also prevent the development of some cases of MDD.…”